Abstract 1562: Efficient antigen presentation and induction of anti-tumor immunity by dendritic cells loaded with antigens by electroporation
Authors: Nagaoka Koji , Takahara Masashi , Yoshimoto Takayuki , Teruya Tsuyoshi , Shiroma Hiroshi , Maekawa Ryuji 
Published: August 2012

Abstract
For successful dendritic cell (DC) therapy of cancer, it is important to choose the optimal method to load DCs with antigens to induce higher anti-tumor immunity, particularly tumor-specific CTL responses. The co-incubation (Co) method is conventionally used to load DCs with tumor antigens in DC therapy. Although DCs could uptake tumor antigens by endocytosis in this method, they are thought to be processed in lysosome and presented mainly on MHC class II, but not efficiently on MHC class I. Electroporation (Ep) is one of the promising antigen-loading method because it is reported that DCs could uptake much larger amount of FITC-dextran by Ep in comparison with Co method. In this study, we performed side-by-side comparisons of these two antigen loading methods using murine bone marrow derived DCs. First, we compared antigen presentation using purified ovalbumin (OVA) and OVA-specific OT-I CD8 and OT-II CD4 T cells. To this end, DCs were loaded with OVA by either Co or Ep, and subsequently cultured with T cells. Two or three days later, T cell expansion and cytokine production were evaluated. As expected, OVA-Co-DCs induced moderate expansion and cytokine production of OT-II T cells, but had little effect on OT-I T cells. In contrast, OVA-Ep-DCs potently stimulated both OT-I and OT-II T cells to expand and produce cytokines, such as IL-2 and IFN-γ. Using monoclonal antibody specific for MHC class I/OVA peptide complex, we confirmed efficient presentation of the OVA peptide on MHC class I by OVA-Ep-DCs. Furthermore, when we used the lysate of EG7 tumor cell line (OVA gene-transfected) as antigen instead of purified OVA, Ep-DCs induced expansion of both OT-I and OT-II T cells efficiently compared with Co-DCs. In the case of Alexa488-OVA, unexpectedly, similar amounts of uptake were seen in Ep-DCs and Co-DCs by FCM analysis. By using confocal microscopy, however, there was a critical difference of intracellular localization of Alexa488-OVA. Although Alexa488-OVA was localized in intracellular vesicles of both DCs, the cytosolic localization was observed only in Ep-DCs, suggesting that antigen loaded by Ep entered cytosol of DCs and would be processed by proteasome and presented on MHC class I efficiently. Finally, to determine the ability of these DCs to induce anti-tumor immunity in vivo, mice were subcutaneously immunized twice at 7 days intervals with 3-5 x 105 cells of either OVA-Ep-DCs or OVA-Co-DCs and then challenged with 3 x 106 of EG7 cells at 7 days after the 2nd immunization. When OVA-Co-DCs were used for immunization, tumor formations were partially prevented. On the contrary, mice immunized with OVA-Ep-DCs were almost completely protected from tumor formations. These results demonstrate that DCs loaded with tumor antigens by Ep have greater antigen presentation capacity, especially through MHC class I pathway, and could induce stronger anti-tumor immunity in vivo than those loaded by Co.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1562. doi:1538-7445.AM2012-1562